Drug facts
BrandEliquis (Apixaban)
No generic apixaban has an active Orange Book listing (a generic was first approved 12/23/2019); the latest Eliquis patent or exclusivity in the Orange Book runs to 08/24/2031. 9 staged generic applications passed FDA review and wait on patents or exclusivity.
Eliquis was first approved by the FDA on 12/28/2012 under NDA 202155; the application holder is Bristol Myers Squibb Co Pharmaceutical Research Institute.
The latest NADAC for ELIQUIS 2.5 MG TABLET is $5.51 per unit (as of 10/28/2026).
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
1,758days until the latest Eliquis patent expires
- Latest patent
- 08/24/2031Eliquis Orange Book
- Exclusivity
- 10/17/2028Eliquis Orange Book
- Later patents, other products
- Eliquis Sprinkle 05/22/2041 Orange Book
02Competition
- Generics
- No active generic listing in the Orange Book Orange Book
- Staged generics
- 9 passed FDA review, awaiting market entry FDA
- First generic approved
- 12/23/2019 Orange Book
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $5.51 per unitELIQUIS 2.5 MG TABLET, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Bristol Myers Squibb Co Pharmaceutical Research Institute Orange Book
- Application
- NDA 202155 Orange Book
- First approved
- 12/28/2012 Orange Book
- Dosage forms
- tablet, for suspension; tablet
- Routes
- oral
- Other brand names
- Eliquis Sprinkle
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.